JP2018536710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536710A5 JP2018536710A5 JP2018543283A JP2018543283A JP2018536710A5 JP 2018536710 A5 JP2018536710 A5 JP 2018536710A5 JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018536710 A5 JP2018536710 A5 JP 2018536710A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- daily dose
- statin
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 claims 5
- 229950004781 gemcabene Drugs 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- 102000004146 ATP citrate synthases Human genes 0.000 claims 4
- 108090000662 ATP citrate synthases Proteins 0.000 claims 4
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 4
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 4
- 108010018763 Biotin carboxylase Proteins 0.000 claims 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 229960003765 fluvastatin Drugs 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 229960004844 lovastatin Drugs 0.000 claims 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 3
- 229960002797 pitavastatin Drugs 0.000 claims 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 3
- 229960002965 pravastatin Drugs 0.000 claims 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 3
- 229960000672 rosuvastatin Drugs 0.000 claims 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 3
- 229960002855 simvastatin Drugs 0.000 claims 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010045263 Type IIb hyperlipidaemia Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 230000002440 hepatic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 101150102415 Apob gene Proteins 0.000 claims 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- -1 cholesteryl ester Chemical class 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252147P | 2015-11-06 | 2015-11-06 | |
| US201562252195P | 2015-11-06 | 2015-11-06 | |
| US62/252,195 | 2015-11-06 | ||
| US62/252,147 | 2015-11-06 | ||
| PCT/US2016/060837 WO2017079748A1 (en) | 2015-11-06 | 2016-11-07 | Treatment of mixed dyslipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536710A JP2018536710A (ja) | 2018-12-13 |
| JP2018536710A5 true JP2018536710A5 (cg-RX-API-DMAC7.html) | 2019-12-19 |
Family
ID=58663111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543079A Pending JP2018532808A (ja) | 2015-11-06 | 2016-11-07 | 心血管疾患の処置のためのゲムカベンの組み合わせ |
| JP2018543283A Pending JP2018536710A (ja) | 2015-11-06 | 2016-11-07 | 混合型脂質異常症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543079A Pending JP2018532808A (ja) | 2015-11-06 | 2016-11-07 | 心血管疾患の処置のためのゲムカベンの組み合わせ |
Country Status (16)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| ES2860423T3 (es) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida |
| WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| SG10201912754UA (en) * | 2015-11-06 | 2020-02-27 | Gemphire Therapeutics Inc | Treatment of mixed dyslipidemia |
| JP6963882B2 (ja) | 2016-05-05 | 2021-11-10 | チルドレンズ ホスピタル メディカル センター | 胃底部組織のインビトロでの製造のための方法及び当該方法と関連した組成物 |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| WO2018064373A1 (en) | 2016-09-28 | 2018-04-05 | Eiger Biopharmaceuticals, Inc. | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |
| EP3534907A4 (en) | 2016-11-04 | 2020-06-24 | Children's Hospital Medical Center | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASE |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| CA3059073A1 (en) * | 2017-04-18 | 2018-10-25 | Daniela Carmen Oniciu | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
| CA3077442A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| JP2021504479A (ja) * | 2017-11-28 | 2021-02-15 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 非アルコール性脂肪性肝炎の処置のための方法および医薬組成物 |
| WO2019126626A1 (en) | 2017-12-21 | 2019-06-27 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| SG11202100533VA (en) | 2018-07-26 | 2021-02-25 | Childrens Hospital Med Ct | Hepato-biliary-pancreatic tissues and methods of making same |
| CA3112026A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| TWI825177B (zh) | 2018-09-18 | 2023-12-11 | 大陸商北京強新生物科技有限公司 | 非酒精性脂肪性肝病的治療 |
| CN113286596A (zh) * | 2018-10-12 | 2021-08-20 | 西奈山伊坎医学院 | AZD3355(Lesogaberan)用于治疗和预防非酒精性脂肪性肝炎(NASH)、肝纤维化及其他肝脏病症 |
| EP3867222A4 (en) * | 2018-10-18 | 2022-07-06 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF |
| US12497597B2 (en) | 2019-05-31 | 2025-12-16 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| CN112851660B (zh) * | 2019-11-12 | 2022-03-18 | 广东药科大学 | 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途 |
| CN114957119B (zh) * | 2022-05-05 | 2023-06-16 | 武汉大学中南医院 | 一种四氢喹啉螺1,3-茚二酮类衍生物及其制备方法与应用 |
| WO2025186785A1 (en) * | 2024-03-08 | 2025-09-12 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Oral pharmaceutical composition of pitavastatin, method and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT381664B (de) | 1984-02-07 | 1986-11-10 | Steyr Daimler Puch Ag | Einrichtung zur ueberwachung elektrischer, von einer gesteuerten wechselstromquelle gespeister widerstandsschweissvorgaenge, insbesondere punktschweissungen |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| CA2039763A1 (en) | 1990-04-30 | 1991-10-31 | Henry Y. Pan | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| IL118778A (en) | 1995-07-03 | 1999-07-14 | Sankyo Co | Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor |
| WO1997016187A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| WO1997016181A1 (en) | 1995-11-03 | 1997-05-09 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
| ATE359785T1 (de) * | 1997-07-31 | 2007-05-15 | Kos Life Sciences Inc | Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| NZ503982A (en) | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| US20030105154A1 (en) * | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| AU2003230765A1 (en) * | 2002-03-29 | 2003-10-13 | Bayhill Therapeutics, Inc. | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| EP1572189A1 (en) * | 2002-11-15 | 2005-09-14 | Warner-Lambert Company LLC | Method of lowering crp and reducing systemic inflammation |
| US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| JP2006131559A (ja) * | 2004-11-05 | 2006-05-25 | Takeda Chem Ind Ltd | 含窒素複素環化合物 |
| WO2006054308A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| CA2600429A1 (en) * | 2005-03-08 | 2006-09-14 | Reliant Pharmaceuticals, Inc. | Treatment with statin and omega-3 fatty acids and a combination product thereof |
| US20090186834A1 (en) * | 2005-03-24 | 2009-07-23 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| US20070161578A1 (en) * | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
| JP5457830B2 (ja) * | 2006-04-03 | 2014-04-02 | オディディ，イサ | オルガノゾル被膜を含む制御放出送達デバイス |
| JP5270545B2 (ja) | 2006-08-03 | 2013-08-21 | タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ | フラッシングのないナイアシン類似体およびそれらの使用法 |
| WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| FI20080353A0 (fi) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| US20100144864A1 (en) * | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US9307371B2 (en) | 2008-01-18 | 2016-04-05 | Verizon Patent And Licensing Inc. | Method and system for SMS/MMS messaging to a connected device |
| BRPI0912842A8 (pt) * | 2008-05-20 | 2019-01-29 | Cerenis Therapeutics Holding | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina |
| WO2009151116A1 (ja) * | 2008-06-13 | 2009-12-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| US20120202849A1 (en) | 2009-10-12 | 2012-08-09 | Anil Pareek | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| CA2786071C (en) * | 2010-01-08 | 2021-01-12 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| CA2802945A1 (en) * | 2010-06-24 | 2011-12-29 | Arisaph Pharmaceuticals, Inc. | Niacin mimetics, and methods of use thereof |
| TR201005325A2 (tr) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| CN107648210A (zh) * | 2010-12-27 | 2018-02-02 | 燿石治疗公司 | 用于治疗胰腺炎的吉卡宾和衍生物 |
| EP2604256B1 (en) * | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| CN102525942A (zh) * | 2012-01-05 | 2012-07-04 | 金陵药业股份有限公司 | 一种阿托伐他汀钙肠溶微丸及其制备方法 |
| CA2861643C (en) * | 2012-01-06 | 2020-10-06 | Charles L. Bisgaier | Methods of reducing risk of cardiovascular disease |
| AU2015231076B2 (en) * | 2014-03-20 | 2020-05-21 | Esperion Therapeutics, Inc. | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders |
| CN104127391B (zh) * | 2014-08-05 | 2016-08-24 | 李宝齐 | 一种含有阿托伐他汀钙的固体药物组合物 |
| SG10201912754UA (en) * | 2015-11-06 | 2020-02-27 | Gemphire Therapeutics Inc | Treatment of mixed dyslipidemia |
| CN105434391A (zh) * | 2016-01-18 | 2016-03-30 | 上海蓝心医药科技有限公司 | 阿托伐他汀钙肠溶片及其制备方法和应用 |
-
2016
- 2016-11-07 SG SG10201912754UA patent/SG10201912754UA/en unknown
- 2016-11-07 KR KR1020187013334A patent/KR20180073597A/ko not_active Withdrawn
- 2016-11-07 BR BR112018009238A patent/BR112018009238A8/pt not_active Application Discontinuation
- 2016-11-07 EP EP16863170.3A patent/EP3370713A4/en not_active Withdrawn
- 2016-11-07 CA CA3000016A patent/CA3000016A1/en not_active Abandoned
- 2016-11-07 BR BR112018007857A patent/BR112018007857A2/pt not_active Application Discontinuation
- 2016-11-07 JP JP2018543079A patent/JP2018532808A/ja active Pending
- 2016-11-07 WO PCT/US2016/060849 patent/WO2017079755A1/en not_active Ceased
- 2016-11-07 MX MX2018005096A patent/MX2018005096A/es unknown
- 2016-11-07 MA MA043190A patent/MA43190A/fr unknown
- 2016-11-07 RU RU2018120599A patent/RU2018120599A/ru not_active Application Discontinuation
- 2016-11-07 RU RU2018120726A patent/RU2018120726A/ru not_active Application Discontinuation
- 2016-11-07 AU AU2016349634A patent/AU2016349634A1/en not_active Abandoned
- 2016-11-07 EP EP16863175.2A patent/EP3370703A4/en not_active Withdrawn
- 2016-11-07 CN CN201680064197.2A patent/CN108348491A/zh active Pending
- 2016-11-07 CN CN201680064715.0A patent/CN108366957A/zh active Pending
- 2016-11-07 WO PCT/US2016/060837 patent/WO2017079748A1/en not_active Ceased
- 2016-11-07 CA CA3001627A patent/CA3001627A1/en not_active Abandoned
- 2016-11-07 HK HK19101864.0A patent/HK1259458A1/zh unknown
- 2016-11-07 HK HK19100291.5A patent/HK1257929A1/zh unknown
- 2016-11-07 KR KR1020187014906A patent/KR20180073665A/ko not_active Withdrawn
- 2016-11-07 SG SG11201803442UA patent/SG11201803442UA/en unknown
- 2016-11-07 AU AU2016348638A patent/AU2016348638A1/en not_active Abandoned
- 2016-11-07 JP JP2018543283A patent/JP2018536710A/ja active Pending
- 2016-11-07 MX MX2018005540A patent/MX2018005540A/es unknown
-
2017
- 2017-01-26 US US15/416,911 patent/US9849104B2/en active Active
- 2017-02-03 US US15/424,620 patent/US20170172955A1/en not_active Abandoned
- 2017-11-16 US US15/814,557 patent/US10449154B2/en active Active
-
2018
- 2018-04-22 IL IL258819A patent/IL258819A/en unknown
- 2018-05-04 PH PH12018500972A patent/PH12018500972A1/en unknown
- 2018-05-04 US US15/971,491 patent/US20180325825A1/en not_active Abandoned
- 2018-05-04 IL IL259133A patent/IL259133A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536710A5 (cg-RX-API-DMAC7.html) | ||
| RU2018120599A (ru) | Лечение смешанной дислипидемии | |
| Mani et al. | Niacin therapy, HDL cholesterol, and cardiovascular disease: is the HDL hypothesis defunct? | |
| JP2022116083A5 (cg-RX-API-DMAC7.html) | ||
| JP2018104452A (ja) | 心血管疾患のリスクを低減する方法 | |
| FI3911648T3 (fi) | 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön | |
| JP2016538248A5 (cg-RX-API-DMAC7.html) | ||
| JP2012097105A5 (cg-RX-API-DMAC7.html) | ||
| RU2018111327A (ru) | Способ ингибирования всасывания и/или повышения выведения липидов с использованием d-псикозы | |
| RU2017136295A (ru) | Фиксированные комбинации и составы, содержащие етс1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания | |
| EP3035934A2 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2012505905A5 (cg-RX-API-DMAC7.html) | ||
| JP2017519028A5 (cg-RX-API-DMAC7.html) | ||
| Salakhutdinov et al. | Triglyceride-lowering agents | |
| JP2007527433A5 (cg-RX-API-DMAC7.html) | ||
| US7776354B2 (en) | Remedies for glomerular diseases | |
| JP2018027953A (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
| JP2019533705A5 (cg-RX-API-DMAC7.html) | ||
| JP2014509305A5 (cg-RX-API-DMAC7.html) | ||
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| KR20230142523A (ko) | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 | |
| Park et al. | KOREAN ROSUVASTATIN EFFECTIVENESS STUDY IN NONDIABETIC METABOLIC SYNDROME (KREST) | |
| Chapman | Current drug information: Excess cardiovascular risk in inflammatory rheumatic diseases | |
| Paragh et al. | ANIMAL MODEL FOR SIMULTANEOUS STUDY OF STATIN-EFFECTS AGAINST HYPERCHOLESTEROLEMIA AND TUMOR DEVELOPMENT | |
| Blom et al. | Rosuvastatin reduces non-HDL-cholesterol and lipoprotein remnants in Fredrickson type III hyperlipoproteinaemia patients |